特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
938722

コロナウイルスワクチンの世界市場:2025年までの予測と市場機会

Global Coronavirus Vaccine Market By Infection Type, By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Forecast & Opportunities, 2025

出版日: | 発行: TechSci Research | ページ情報: 英文 120 Pages | 納期: お問合せ

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

コロナウイルスワクチンの世界市場:2025年までの予測と市場機会
出版日: 2020年05月01日
発行: TechSci Research
ページ情報: 英文 120 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 目次
概要

世界のコロナウイルスワクチン市場は、予測期間中に強力な速度で成長すると予想されています。 世界のコロナウイルスワクチン市場は、世界中のさまざまな地域でのこの疾患の有病率の増加に牽引されています。これにより、ウイルス保護の必要性が高まり、市場の成長にプラスの影響を与えており、さらに、潜在的なワクチンの開発のためのさまざまな製薬およびバイオテクノロジー企業による研究開発活動の増加は、市場の成長を促進すると予想されます。

当レポートは、世界のコロナウイルスワクチン市場をセグメント別や地域別で調査したもので、市場規模および市場シェアの予測、促進要因と課題、市場動向、競合情勢、企業プロファイルなどの情報を提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 COVID-19の影響

第4章 エグゼクティブサマリー

第5章 顧客の声

第6章 世界のコロナウイルスワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 感染タイプ別(HCoV-229E、HCoV-OC43、SARS-CoV、New Haven CoV、HKU1-CoV、MERS-CoV、SARS-CoV-2、その他)
    • ワクチンタイプ別(不活化コロナウイルスワクチン、弱毒生コロナウイルスワクチン、Sタンパク質ベースのコロナウイルスワクチン)
    • 製品タイプ 別(一価ワクチン、多変量ワクチン)
    • 投与経路別(経口、筋肉内、皮下)
    • 患者タイプ別(小児、成人)
    • エンドユーザ別(病院、診療所、研究機関、その他)
    • 会社別
    • 地域別
  • 製品市場マップ

第7章 アジア太平洋のコロナウイルスワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 感染タイプ別
    • ワクチンタイプ別
    • 製品タイプ別
    • 投与経路別
    • 患者タイプ別
    • エンドユーザー別
    • 国別
  • アジア太平洋:国分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国
    • 香港
    • タイ
    • シンガポール

第8章 欧州のコロナウイルスワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 感染タイプ別
    • ワクチンタイプ別
    • 製品タイプ別
    • 投与経路別
    • 患者タイプ別
    • エンドユーザー別
    • 国別
  • 欧州:国分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 北米のコロナウイルスワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 感染タイプ別
    • ワクチンタイプ別
    • 製品タイプ別
    • 投与経路別
    • 患者タイプ別
    • エンドユーザー別
    • 国別
  • 北米:国分析
    • 米国
    • メキシコ
    • カナダ

第10章 南米のコロナウイルスワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 感染タイプ別
    • ワクチンタイプ別
    • 製品タイプ別
    • 投与経路別
    • 患者タイプ別
    • エンドユーザー別
    • 国別
  • 南米:国分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカのコロナウイルスワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 感染タイプ別
    • ワクチンタイプ別
    • 製品タイプ別
    • 投与経路別
    • 患者タイプ別
    • エンドユーザー別
    • 国別
  • 中東・アフリカ:国分析
    • 南アフリカ
    • サウジアラビア
    • UAE
    • クウェート

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

第14章 特許分析

第15章 競合情勢

  • 競合の展望
  • 企業プロファイル
  • 会社の詳細
  • 財務
  • サプライ/ バリューチェーン分析
  • 医薬品開発から発売までのタイムライン
    • ワクチン承認状況
  • SWOT分析
  • 主要市場の焦点と地理的存在
  • 計画投資
  • 市場ポジショニング
  • 主要プレーヤーのプロファイル
    • Inovio Pharmaceuticals, Inc.
    • Moderna, Inc.
    • Novavax, Inc.
    • Johnson & Johnson
    • Pfizer
    • Sanofi
    • Protein Potential, LLC
    • AlphaVax, Inc.
    • Synairgen PLC
    • NanoViricides, Inc.
    • GeneCure, LLC
    • GlaxoSmithKline (GSK)
    • Zydus Cadila
    • Serum Institute
    • Bharat Biotech
    • CanSino Biological Inc
    • FluGen
    • I-Mab Biopharma
    • Medicago
    • Airway Therapeutics

第16章 戦略的推奨事項

第17章 免責事項

目次
Product Code: 4694

Coronaviruses are a group of viruses belonging to the coronaviridae family that can affect both mammals and birds. The common symptoms include mild illness such as common cold, respiratory tract infections, while the lethal symptoms comprise of SARS, MERS, SARS-COV-2, among others.

The ongoing pandemic novel coronavirus disease (COVID-19) is caused due to SARS-COV-2 and generally spreads from animals to humans and then from humans to humans. The disease usually spreads from the saliva droplets of the infected person or the nose discharges of the infected person when they cough or sneeze. The first case of the disease was reported in December 2019 in Wuhan, China and since then, it has spread to various parts of the world infecting millions. As of 13th April 2020, coronavirus has affected around 210 countries & territories with the total number of coronavirus cases reaching 1,854,043 out of which 427,879 have recovered and around 114,291 people have succumbed to the disease.

Global coronavirus vaccine market is expected to grow at a robust rate during the forecast period. The global coronavirus vaccine market is driven by the increasing prevalence of this disease across different parts of the globe. This has increased the need to protect the world from the virus, thereby expected to positively impact the market growth. Furthermore, increasing R&D activities by various pharmaceutical & biotechnology players for the development of potential vaccines is anticipated to foster the market growth. According to WHO, there are 70 coronavirus vaccines under development by different companies and organizations. Out of these, three vaccines are already being tested in human trials. The vaccine developed by the Hong Kong based biopharmaceutical firm CanSino Biologics Inc. and the Beijing Institute of Biotechnology is leading the race and is currently in the second phase of clinical trials. On the other hand, other vaccines developed by the US-based companies Moderna Inc. and Inovio Pharmaceuticals Inc., have also started their human trials.

The global coronavirus vaccine market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end user, company and region. Based on infection type, the market can be categorized into HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2 and others. The SARS-CoV-2 segment is expected to dominate the market since this infection or virus is the cause of the pandemic COVID-19 disease.

Regionally, the global coronavirus vaccine market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these, Asia-Pacific is expected to witness significant growth during the forecast period in the overall coronavirus vaccine market since China was the epicenter for the novel coronavirus disease and various Chinese companies & research institutes have already started working on various treatment options and vaccines to fight the disease. Additionally, other countries in the region such as India, Singapore, South Korea are also aggressively involved in developing vaccines and other treatments to curb the disease.

Major players operating in the global coronavirus vaccine market include Inovio Pharmaceuticals, Inc., Moderna, Inc., Novavax, Inc., Johnson & Johnson, Pfizer, Sanofi, Protein Potential, LLC, AlphaVax, Inc., Synairgen PLC, NanoViricides, Inc., GeneCure, LLC, GlaxoSmithKline (GSK), Zydus Cadila, Serum Institute, Bharat Biotech, CanSino Biological Inc, FluGen, I-Mab Biopharma, Medicago, Airway Therapeutics and others. The companies are developing advanced technologies and launching new services in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.

Years considered for this report:

Historical Year: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study:

  • To analyze and estimate the market size of global coronavirus vaccine market from 2015 to 2018.
  • To estimate and forecast the market size of global coronavirus vaccine market from 2019 to 2025 and growth rate until 2025.
  • To classify and forecast global coronavirus vaccine market based on infection type, vaccine type, product type, route of administration, patient type, end user, company and regional distribution.
  • To identify dominant region or segment in the global coronavirus vaccine market.
  • To identify drivers and challenges for global coronavirus vaccine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global coronavirus vaccine market.
  • To conduct pricing analysis for global coronavirus vaccine market.
  • To identify and analyze the profile of leading players operating in global coronavirus vaccine market.
  • To identify key sustainable strategies adopted by market players in global coronavirus vaccine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global coronavirus vaccine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Coronavirus vaccine manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to coronavirus vaccine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global coronavirus vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Coronavirus Vaccine Market, By Infection Type:

HCoV-229E

HCoV-OC43

SARS-CoV

New Haven CoV

HKU1-CoV

MERS-CoV

SARS-CoV-2

Others

  • Global Coronavirus Vaccine Market, By Vaccine Type:

Inactivated Coronavirus Vaccine

Live Attenuated Coronavirus Vaccine

S-Protein Based Coronavirus Vaccine

  • Global Coronavirus Vaccine Market, By Product Type:

Monovalent Vaccine

Multivariant Vaccine

  • Global Coronavirus Vaccine Market, By Route of Administration:

Oral

Intramuscular

Subcutaneous

  • Global Coronavirus Vaccine Market, By Patient Type:

Pediatric

Adult

  • Global Coronavirus Vaccine Market, By End User:

Hospitals

Clinics

Research Institutes

Others

  • Global Coronavirus Vaccine Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Hong Kong
  • Thailand
  • Singapore

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Iran

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global coronavirus vaccine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Coronavirus Vaccine Market

4. Executive Summary

5. Voice of Customer

6. Global Coronavirus Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2, Others)
    • 6.2.2. By Vaccine Type (Inactivated Coronavirus Vaccine, Live Attenuated Coronavirus Vaccine, S-Protein Based Coronavirus Vaccine)
    • 6.2.3. By Product Type (Monovalent Vaccine v/s Multivariant Vaccine)
    • 6.2.4. By Route of Administration (Oral, Intramuscular, Subcutaneous)
    • 6.2.5. By Patient Type (Pediatric v/s Adult)
    • 6.2.6. By End User (Hospitals, Clinics, Research Institutes, Others)
    • 6.2.7. By Company (2019)
    • 6.2.8. By Region
  • 6.3. Product Market Map

7. Asia-Pacific Coronavirus Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Infection Type
    • 7.2.2. By Vaccine Type
    • 7.2.3. By Product Type
    • 7.2.4. By Route of Administration
    • 7.2.5. By Patient Type
    • 7.2.6. By End User
    • 7.2.7. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Coronavirus Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Infection Type
        • 7.3.1.2.2. By Vaccine Type
        • 7.3.1.2.3. By Product Type
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By Patient Type
        • 7.3.1.2.6. By End User
    • 7.3.2. India Coronavirus Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Infection Type
        • 7.3.2.2.2. By Vaccine Type
        • 7.3.2.2.3. By Product Type
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By Patient Type
        • 7.3.2.2.6. By End User
    • 7.3.3. Australia Coronavirus Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Infection Type
        • 7.3.3.2.2. By Vaccine Type
        • 7.3.3.2.3. By Product Type
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By Patient Type
        • 7.3.3.2.6. By End User
    • 7.3.4. Japan Coronavirus Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Infection Type
        • 7.3.4.2.2. By Vaccine Type
        • 7.3.4.2.3. By Product Type
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By Patient Type
        • 7.3.4.2.6. By End User
    • 7.3.5. South Korea Coronavirus Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Infection Type
        • 7.3.5.2.2. By Vaccine Type
        • 7.3.5.2.3. By Product Type
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By Patient Type
        • 7.3.5.2.6. By End User
    • 7.3.6. Hong Kong Coronavirus Vaccine Market Outlook
      • 7.3.6.1. Market Size & Forecast
        • 7.3.6.1.1. By Value
      • 7.3.6.2. Market Share & Forecast
        • 7.3.6.2.1. By Infection Type
        • 7.3.6.2.2. By Vaccine Type
        • 7.3.6.2.3. By Product Type
        • 7.3.6.2.4. By Route of Administration
        • 7.3.6.2.5. By Patient Type
        • 7.3.6.2.6. By End User
    • 7.3.7. Thailand Coronavirus Vaccine Market Outlook
      • 7.3.7.1. Market Size & Forecast
        • 7.3.7.1.1. By Value
      • 7.3.7.2. Market Share & Forecast
        • 7.3.7.2.1. By Infection Type
        • 7.3.7.2.2. By Vaccine Type
        • 7.3.7.2.3. By Product Type
        • 7.3.7.2.4. By Route of Administration
        • 7.3.7.2.5. By Patient Type
        • 7.3.7.2.6. By End User
    • 7.3.8. Singapore Coronavirus Vaccine Market Outlook
      • 7.3.8.1. Market Size & Forecast
        • 7.3.8.1.1. By Value
      • 7.3.8.2. Market Share & Forecast
        • 7.3.8.2.1. By Infection Type
        • 7.3.8.2.2. By Vaccine Type
        • 7.3.8.2.3. By Product Type
        • 7.3.8.2.4. By Route of Administration
        • 7.3.8.2.5. By Patient Type
        • 7.3.8.2.6. By End User

8. Europe Coronavirus Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Infection Type
    • 8.2.2. By Vaccine Type
    • 8.2.3. By Product Type
    • 8.2.4. By Route of Administration
    • 8.2.5. By Patient Type
    • 8.2.6. By End User
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Coronavirus Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Infection Type
        • 8.3.1.2.2. By Vaccine Type
        • 8.3.1.2.3. By Product Type
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By Patient Type
        • 8.3.1.2.6. By End User
    • 8.3.2. Germany Coronavirus Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Infection Type
        • 8.3.2.2.2. By Vaccine Type
        • 8.3.2.2.3. By Product Type
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By Patient Type
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom Coronavirus Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Infection Type
        • 8.3.3.2.2. By Vaccine Type
        • 8.3.3.2.3. By Product Type
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By Patient Type
        • 8.3.3.2.6. By End User
    • 8.3.4. Italy Coronavirus Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Infection Type
        • 8.3.4.2.2. By Vaccine Type
        • 8.3.4.2.3. By Product Type
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By Patient Type
        • 8.3.4.2.6. By End User
    • 8.3.5. Spain Coronavirus Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Infection Type
        • 8.3.5.2.2. By Vaccine Type
        • 8.3.5.2.3. By Product Type
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By Patient Type
        • 8.3.5.2.6. By End User

9. North America Coronavirus Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Infection Type
    • 9.2.2. By Vaccine Type
    • 9.2.3. By Product Type
    • 9.2.4. By Route of Administration
    • 9.2.5. By Patient Type
    • 9.2.6. By End User
    • 9.2.7. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Coronavirus Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Infection Type
        • 9.3.1.2.2. By Vaccine Type
        • 9.3.1.2.3. By Product Type
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By Patient Type
        • 9.3.1.2.6. By End User
    • 9.3.2. Mexico Coronavirus Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Infection Type
        • 9.3.2.2.2. By Vaccine Type
        • 9.3.2.2.3. By Product Type
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By Patient Type
        • 9.3.2.2.6. By End User
    • 9.3.3. Canada Coronavirus Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Infection Type
        • 9.3.3.2.2. By Vaccine Type
        • 9.3.3.2.3. By Product Type
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By Patient Type
        • 9.3.3.2.6. By End User

10. South America Coronavirus Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Infection Type
    • 10.2.2. By Vaccine Type
    • 10.2.3. By Product Type
    • 10.2.4. By Route of Administration
    • 10.2.5. By Patient Type
    • 10.2.6. By End User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Coronavirus Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Infection Type
        • 10.3.1.2.2. By Vaccine Type
        • 10.3.1.2.3. By Product Type
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By Patient Type
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina Coronavirus Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Infection Type
        • 10.3.2.2.2. By Vaccine Type
        • 10.3.2.2.3. By Product Type
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By Patient Type
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia Coronavirus Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Infection Type
        • 10.3.3.2.2. By Vaccine Type
        • 10.3.3.2.3. By Product Type
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By Patient Type
        • 10.3.3.2.6. By End User

11. Middle East and Africa Coronavirus Vaccine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Infection Type
    • 11.2.2. By Vaccine Type
    • 11.2.3. By Product Type
    • 11.2.4. By Route of Administration
    • 11.2.5. By Patient Type
    • 11.2.6. By End User
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Coronavirus Vaccine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Infection Type
        • 11.3.1.2.2. By Vaccine Type
        • 11.3.1.2.3. By Product Type
        • 11.3.1.2.4. By Route of Administration
        • 11.3.1.2.5. By Patient Type
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia Coronavirus Vaccine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Infection Type
        • 11.3.2.2.2. By Vaccine Type
        • 11.3.2.2.3. By Product Type
        • 11.3.2.2.4. By Route of Administration
        • 11.3.2.2.5. By Patient Type
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE Coronavirus Vaccine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Infection Type
        • 11.3.3.2.2. By Vaccine Type
        • 11.3.3.2.3. By Product Type
        • 11.3.3.2.4. By Route of Administration
        • 11.3.3.2.5. By Patient Type
        • 11.3.3.2.6. By End User
    • 11.3.4. Kuwait Coronavirus Vaccine Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Infection Type
        • 11.3.4.2.2. By Vaccine Type
        • 11.3.4.2.3. By Product Type
        • 11.3.4.2.4. By Route of Administration
        • 11.3.4.2.5. By Patient Type
        • 11.3.4.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Patent Analysis

15. Competitive Landscape

  • 15.1. Competition Outlook
  • 15.2. Company Profiles
  • 15.3. Company Details
  • 15.4. Financials (As Reported)
  • 15.5. Supply/ Value Chain Analysis
  • 15.6. Timelines For Drug Development To Commercial Launch
    • 15.6.1. Status of Approval of vaccines
  • 15.7. SWOT Analysis
  • 15.8. Key Market Focus and Geographical Presence
  • 15.9. Planned Investments
  • 15.10. Market Positioning
  • 15.11. Leading Players Profiled
    • 15.11.1. Inovio Pharmaceuticals, Inc.
    • 15.11.2. Moderna, Inc.
    • 15.11.3. Novavax, Inc.
    • 15.11.4. Johnson & Johnson
    • 15.11.5. Pfizer
    • 15.11.6. Sanofi
    • 15.11.7. Protein Potential, LLC
    • 15.11.8. AlphaVax, Inc.
    • 15.11.9. Synairgen PLC
    • 15.11.10. NanoViricides, Inc.
    • 15.11.11. GeneCure, LLC
    • 15.11.12. GlaxoSmithKline (GSK)
    • 15.11.13. Zydus Cadila
    • 15.11.14. Serum Institute
    • 15.11.15. Bharat Biotech
    • 15.11.16. CanSino Biological Inc
    • 15.11.17. FluGen
    • 15.11.18. I-Mab Biopharma
    • 15.11.19. Medicago
    • 15.11.20. Airway Therapeutics

16. Strategic Recommendations

17. About Us & Disclaimer

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.